Charming Medical ($CMMD) IPO Misstatements and Regulatory Risks

S.D. New York

Court

1:25-cv-10535

Case number

10/21/2025

Class period Start

11/12/2025

Class period End

02/17/2026

Lead Plaintiff motion deadline

$CMMD investors filed a claim against Charming Medical Limited for allegedly failing to disclose known risks and regulatory uncertainties related to its robotic surgical products during its IPO.
After reporting poor financial results and disclosing that it had not obtained required regulatory clearances in China, $CMMD fell 41% from its IPO price within weeks of listing.
$CMMD investors can join this case to be notified about potential recovery.
Case Details:

Charming Medical Limited is a China-based medical device company focused on surgical robots and endoscopy systems. On October 13, 2023, the company completed its U.S. IPO, offering 3 million American Depository Shares (ADSs) at $9.00 per share, raising approximately $27 million. In its offering documents, the company claimed that its flagship product, the Huicheng System—a single-port robotic surgical system—was commercially launched and actively marketed.

However, the IPO materials allegedly omitted key facts: Charming had not yet secured regulatory approval in China for the Huicheng System, and the National Medical Products Administration (NMPA) had not cleared it for wide clinical use. The company also failed to disclose the material impact this lack of approval would have on near-term sales and commercialization.

Following its public debut, Charming’s stock declined steadily. On December 18, 2025, a class action was filed, highlighting post-IPO financial underperformance and the growing realization that the Huicheng System lacked regulatory clearance in key markets. By then, the stock had fallen more than 41% from its IPO price.

Based on these events, $CMMD investors filed a claim against Charming Medical, alleging the company:
It misled investors by stating that its core product was market-ready and commercially viable.
It failed to disclose that it lacked regulatory approval in China for key devices.
It omitted risks that materially affected its ability to generate revenue post-IPO.
Investors argue Charming Medical gave a false impression of its commercialization readiness, resulting in losses once the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Misleading Statements,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

11/12/2025

Filing date

12/22/2025

Lead Plaintiff Deadline

02/17/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.